ESC 365 - Pharmacological blockade of histone methyltransferase SETD7 restores angiogenic response in experimental diabetes

ESC Premium Access

Pharmacological blockade of histone methyltransferase SETD7 restores angiogenic response in experimental diabetes

Session: Congress committee e-posters choice in basic science

Topic: Genetics, Epigenetics, ncRNA

Speaker: Mr S. Mohammed (Zurich, CH)

Event: ESC Congress 2021 - The Digital Experience

Congress Session

About the speaker

Mr Shafeeq Ahmed Mohammed

University of Zurich, Zurich (Switzerland)

0 follower

19 more presentations in this session

Activated myofibroblasts promote cardiac hypertrophy and systolic dysfunction independently of cardiac fibrosis in experimental autoimmune myocarditis

Speaker: Ms K. Tkacz (Cracow, PL)

New insights into the development of radiation-induced cardiac damage using a mouse model

Speaker: Doctor S. Mrotzek (Essen, DE)

The m6A methyltransferase METTL3 promotes hypoxic pulmonary arterial hypertension via targeting PTEN

Speaker: Doctor Y. Qin (Nanjing, CN)

Senescent endothelial cells exacerbate pulmonary hypertension through notch-mediated juxtacrine interaction with pulmonary artery smooth muscle cells

Speaker: Doctor R. Ramadhiani (Kobe, JP)

The transcriptional landscape of the clustered protocadherins in the cardiovascular system

Speaker: Miss W. Zhu (Hong Kong, CN)

Access the full session

Congress committee e-posters choice in basic science

Speakers: Mr S. Mohammed, Ms K. Tkacz, Doctor S. Mrotzek, Doctor Y. Qin, Doctor R. Ramadhiani...

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

ESC Premium Access

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

The novel ageing-induced long non-coding RNA MIRIAL controls endothelial cell and mitochondrial function

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

This platform is supported by